Tan Y, Yoon D, Davies A, Buske C, Boo Y, Somasundaram N
Discov Oncol. 2025; 16(1):181.
PMID: 39951161
PMC: 11828776.
DOI: 10.1007/s12672-025-01860-5.
Tsutsue S, Makita S, Asou H, Wada S, Lee W, Ainiwaer D
PLoS One. 2025; 20(2):e0317439.
PMID: 39913543
PMC: 11801729.
DOI: 10.1371/journal.pone.0317439.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J
Nat Med. 2025; .
PMID: 39833408
DOI: 10.1038/s41591-024-03478-6.
Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A
J Immunother Cancer. 2025; 13(1).
PMID: 39824527
PMC: 11749597.
DOI: 10.1136/jitc-2024-008876.
Yang X, Wang F, Yuan X, Yang B, Chen J, Cheng J
Front Immunol. 2025; 15:1466443.
PMID: 39763668
PMC: 11701372.
DOI: 10.3389/fimmu.2024.1466443.
SMAD4 Regulates the Expression of LCK Affecting Chimeric Antigen Receptor-T Cells Proliferation Through PI3K/Akt Signaling Pathway.
Wan R, Fu B, Fu X, Liu Z, Simayi N, Fu Y
J Cell Physiol. 2025; 240(1):e31520.
PMID: 39763264
PMC: 11704455.
DOI: 10.1002/jcp.31520.
CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?.
Rangel-Pelaez C, Martinez-Gutierrez L, Tristan-Manzano M, Callejas J, Ortego-Centeno N, Martin F
Front Immunol. 2025; 15:1502712.
PMID: 39742256
PMC: 11685126.
DOI: 10.3389/fimmu.2024.1502712.
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.
Luo X, Chen A, Qin L, Weinkove R, Zhao R, Ye T
Front Immunol. 2024; 15:1497736.
PMID: 39717765
PMC: 11663888.
DOI: 10.3389/fimmu.2024.1497736.
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.
Luan D, DeWolf S, Fei T, Raj S, Shah G, Lareau C
Blood Cancer Discov. 2024; 6(2):119-130.
PMID: 39666878
PMC: 11876948.
DOI: 10.1158/2643-3230.BCD-24-0163.
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W
Cancer Cell. 2024; 43(1):49-68.e9.
PMID: 39642889
PMC: 11732734.
DOI: 10.1016/j.ccell.2024.11.006.
Chimeric antigen receptor T-cell therapy in autoimmune diseases.
Liu J, Zhao Y, Zhao H
Front Immunol. 2024; 15:1492552.
PMID: 39628482
PMC: 11611814.
DOI: 10.3389/fimmu.2024.1492552.
Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.
Morabito F, Martino E, Nizzoli M, Talami A, Pozzi S, Martino M
Eur J Haematol. 2024; 114(1):4-16.
PMID: 39462177
PMC: 11613673.
DOI: 10.1111/ejh.14335.
CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
Abdalhadi H, Chatham W, Alduraibi F
Int J Mol Sci. 2024; 25(19).
PMID: 39408836
PMC: 11476835.
DOI: 10.3390/ijms251910511.
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.
Hu J, Dunbar C
Blood. 2024; 144(24):2473-2481.
PMID: 39393068
PMC: 11862814.
DOI: 10.1182/blood.2024025828.
Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia.
Ma J, Yan J, Liu M, Yan C, Tang X, Qiu H
Hemasphere. 2024; 8(10):e70007.
PMID: 39380843
PMC: 11456753.
DOI: 10.1002/hem3.70007.
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Ramdial J, Lin R, Thall P, Valdez B, Hosing C, Srour S
Bone Marrow Transplant. 2024; 59(12):1754-1762.
PMID: 39341929
PMC: 11611727.
DOI: 10.1038/s41409-024-02394-0.
CAR T-cells for pediatric solid tumors: where to go from here?.
Trautmann T, Yakobian N, Nguyen R
Cancer Metastasis Rev. 2024; 43(4):1445-1461.
PMID: 39317919
PMC: 11554711.
DOI: 10.1007/s10555-024-10214-6.
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?.
Bouziana S, Bouzianas D
Int J Mol Sci. 2024; 25(17).
PMID: 39273462
PMC: 11395546.
DOI: 10.3390/ijms25179518.
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.
Tix T, Alhomoud M, Shouval R, Cliff E, Perales M, Cordas Dos Santos D
Clin Cancer Res. 2024; 30(20):4690-4700.
PMID: 39256908
PMC: 11546643.
DOI: 10.1158/1078-0432.CCR-24-1798.
Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Sykorova A, Folber F, Polgarova K, Mocikova H, Duras J, Steinerova K
Cancer Med. 2024; 13(17):e70138.
PMID: 39248284
PMC: 11382134.
DOI: 10.1002/cam4.70138.
